$154 Million is the total value of Corriente Advisors, LLC's 16 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 55.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $23,013,000 | -16.1% | 147,500 | -22.4% | 14.91% | -49.6% |
| Sell | APTOSE BIOSCIENCES INC | $17,487,000 | +0.9% | 2,771,312 | -5.0% | 11.33% | -39.4% | |
| CUE | Sell | CUE BIOPHARMA INC | $16,176,000 | +39.0% | 659,987 | -19.5% | 10.48% | -16.6% |
| PIRS | Sell | PIERIS PHARMACEUTICALS INC | $837,000 | -79.4% | 270,000 | -84.8% | 0.54% | -87.6% |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -3,021,692 | -100.0% | -1.35% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -148,666 | -100.0% | -1.60% | – |
| SDGR | Exit | SCHRODINGER ORD | $0 | – | -60,000 | -100.0% | -2.79% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -230,000 | -100.0% | -3.85% | – |
| Exit | GRAYSCALE BITCOIN ORD | $0 | – | -590,000 | -100.0% | -4.54% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CUE BIOPHARMA INC | 8 | Q3 2021 | 26.7% |
| MAXAR TECHNOLOGIES INC | 7 | Q2 2021 | 41.3% |
| REATA PHARMACEUTICALS INC | 6 | Q2 2021 | 29.6% |
| REPLIMUNE GROUP INC | 5 | Q2 2021 | 12.1% |
| APTOSE BIOSCIENCES INC | 5 | Q4 2020 | 18.7% |
| CARDIFF ONCOLOGY INC | 5 | Q2 2021 | 9.5% |
| DIAMEDICA THERAPEUTICS INC | 5 | Q2 2021 | 2.9% |
| TFF PHARMACEUTICALS INC | 4 | Q3 2021 | 15.2% |
| INVESCO QQQ TR | 3 | Q3 2022 | 94.7% |
| LANTERN PHARMA INC | 3 | Q3 2021 | 13.5% |
View Corriente Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cardiff Oncology, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cue Biopharma, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| TFF Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| NAUTILUS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| Maxar Technologies Inc. | November 26, 2019 | 2,920,750 | 4.9% |
| CATABASIS PHARMACEUTICALS INC | February 23, 2018 | 1,692,899 | 7.3% |
| NEUROLOGIX INC/DE | February 14, 2011 | 16,858,224 | 37.7% |
| AMERICAN VANTAGE COMPANIESSold out | February 16, 2010 | 0 | 0.0% |
| AspenBio Pharma, Inc.Sold out | February 16, 2010 | 0 | 0.0% |
View Corriente Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-15 |
| SC 13G/A | 2022-02-14 |
View Corriente Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.